Sign in4 stories
Tango is moving toward late-stage development of vopimetostat with daraxonrasib in pancreatic cancer after early combination data, while holding $1.0 billion in cash.
SEC filing
New AURORAS-1 data showed 57% response rate in pancreatic cancer patients, as Erasca advances toward three potentially registration-enabling trials backed by a $632.5 million offering.
SEC filing
The oncologist and former Genentech/Roche executive joined the biotech effective August 10, 2026, with an equity package including 1,300,000 stock options.
SEC filing
The precision oncology company sold 31,428,572 shares, with underwriters getting an option for millions more, in a deal set to close July 15, 2026.
SEC filing (3)